Moraxella Keratitis: A Case Series.
Journal
Eye & contact lens
ISSN: 1542-233X
Titre abrégé: Eye Contact Lens
Pays: United States
ID NLM: 101160941
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
accepted:
31
07
2021
pubmed:
15
9
2021
medline:
24
11
2021
entrez:
14
9
2021
Statut:
ppublish
Résumé
To report the ocular and systemic risk factors, clinical manifestations, and management outcomes of Moraxella keratitis. This retrospective study included patients with culture-proven Moraxella keratitis in South Texas between 2012 and 2018. Clinical data including demographics, ocular and systemic risk factors, clinical presentation, speciation, and treatment course were collected. Fourteen eyes of 14 patients had culture-proven Moraxella keratitis which made up 8.1% of cases of culture-proven bacterial keratitis in the period studied. These included 10 men and 4 women with a mean age of 52.7±11.3 years. Ten patients (71.4%) had different ocular risk factors such as ocular trauma, corneal foreign body, contact lens use, preceding viral keratitis, neurotrophic cornea, and recent corneal transplant on topical steroids. Systemic risk factors included diabetes mellitus, systemic immunosuppressive therapy, cancer chemotherapy, and AIDS. There was no specific clinical manifestation. The size of stromal infiltration on initial presentation varied among the cases, with 71.4% stromal infiltrations of 4 mm or less. The patients were managed with fortified tobramycin, fortified vancomycin, and moxifloxacin eye drops. No eyes required surgical intervention during treatment for the active infection, except for one eye with pre-existing no light perception that was enucleated because of chronic pain. Moraxella keratitis is a less frequent form of bacterial keratitis that appears more prevalent in patients with previous ocular conditions. Early diagnosis of this infection and medical treatment with a conventional corneal ulcer regimen can result in good clinical outcomes without the need for a surgical intervention.
Identifiants
pubmed: 34520409
doi: 10.1097/ICL.0000000000000839
pii: 00140068-202112000-00011
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
674-676Informations de copyright
Copyright © 2021 Contact Lens Association of Ophthalmologists.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
Lin A, Rhee MK, Akpek EK, et al. Bacterial keratitis preferred practice Pattern®. Ophthalmology 2019;126:P1–P55.
Austin A, Lietman T, Rose-Nussbaumer J. Update on the management of infectious keratitis. Ophthalmology 2017;124:1678–1689.
Yildiz EH, Airiani S, Hammersmith KM, et al. Trends in contact lens-related corneal ulcers at a tertiary referral center. Cornea 2012;31:1097–1102.
Jin H, Parker WT, Law NW, et al. Evolving risk factors and antibiotic sensitivity patterns for microbial keratitis at a large county hospital. Br J Ophthalmol 2017;101:1483–1487.
Henry CR, Flynn HW, Miller D, et al. Infectious keratitis progressing to endophthalmitis: A 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology 2012;119:2443–2449.
Tan SZ, Walkden A, Au L, et al. Twelve-year analysis of microbial keratitis trends at a UK tertiary hospital. Eye (Lond) 2017;31:1229–1236.
Ting DSJ, Settle C, Morgan SJ, et al. A 10-year analysis of microbiological profiles of microbial keratitis: The North East England Study. Eye (Lond) 2018;32:1416–1417.
McGregor K, Chang BJ, Mee BJ, et al. Moraxella catarrhalis: Clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998;17:219–234.
Puig M, Weiss M, Salinas R, et al. Etiology and risk factors for infectious keratitis in South Texas. J Ophthalmic Vis Res 2020;15:128–137.
Orlans HO, Hornby SJ, Bowler IC. In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: A 10-year review. Eye (Lond) 2011;25:489–493.
National surveillance of infectious keratitis in Japan—Current status of isolates, patient background, and treatment. Nippon Ganka Gakkai Zasshi 2006;110:961–972.
Varaprasathan G, Miller K, Lietman T, et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor foundation. Cornea 2004;23:360–364.
McSwiney TJ, Knowles SJ, Murphy CC. Clinical and microbiological characteristics of Moraxella keratitis. Br J Ophthalmol 2019;103:1704–1709.
Gisselsson-Solen M, Henriksson G, Hermansson A, et al. Risk factors for carriage of AOM pathogens during the first 3 years of life in children with early onset of acute otitis media. Acta Otolaryngol 2014;134:684–690.
Das S, Constantinou M, Daniell M, et al. Moraxella keratitis: Predisposing factors and clinical review of 95 cases. Br J Ophthalmol 2006;90:1236–1238.
Durrani AF, Faith SC, Kowalski RP, et al. Moraxella keratitis: Analysis of risk factors, clinical characteristics, management, and treatment outcomes. Am J Ophthalmol 2019;197:17–22.
Cobo LM, Coster DJ, Peacock J. Moraxella keratitis in a nonalcoholic population. Br J Ophthalmol 1981;65:683–686.
Tobimatsu Y, Inada N, Shoji J, et al. Clinical characteristics of 17 patients with Moraxella keratitis. Semin Ophthalmol 2018;33:726–732.
Mian SI, Malta JB. Moraxella keratitis: Risk factors, presentation, and management. Acta Ophthalmol 2011;89:e208–e209.
Inoue H, Suzuki T, Inoue T, et al. Clinical characteristics and bacteriological profile of Moraxella keratitis. Cornea 2015;34:1105–1109.
Garg P, Mathur U, Athmanathan S, et al. Treatment outcome of Moraxella keratitis: Our experience with 18 cases—A retrospective review. Cornea 1999;18:176–181.
Shih KC, Lam KS, Tong L. A systematic review on the impact of diabetes mellitus on the ocular surface. Nutr Diabetes 2017;7:e251.
Zafar H, Tan SZ, Walkden A, et al. Clinical characteristics and outcomes of Moraxella keratitis. Cornea 2018;37:1551–1554.